无症状肝硬化结构化早期筛查:基于人群的肝脏筛查项目SEAL的结果
SEAL是一项前瞻性队列研究,在德国35岁以上人群健康检查中提供问卷、肝功能检测和随访,对AST/ALT升高者计算APRI,评分>0.5者转诊肝病专家。共纳入11859名参与者,对照组为349570名常规检查者。筛查组检出45例进展性纤维化/肝硬化,排除初始即失代偿肝硬化后,筛查组早期肝硬化检出几率较常规护理高59%(边际OR 1.590,单侧95%CI 1.080,+Inf)。
要点
- SEAL筛查路径包括问卷、AST/ALT检测,升高者计算APRI,评分>0.5转诊肝病专家。
- 筛查组进展性纤维化/肝硬化标准化发病率为3.83‰,对照组为3.36‰。
- 排除初始失代偿肝硬化后,筛查组早期肝硬化检出率3.51‰,对照组2.21‰。
核心结论
- 实施结构化筛查项目可能提高普通人群肝硬化的早期检出率。
- SEAL路径是可行且可能具有成本效益的筛查方案。
研究设计与样本
- SEAL为前瞻性队列研究,对照组来自常规护理数据。
- 在德国35岁以上人群初级保健医生处参加「Check-up 35」健康检查者被提供问卷、肝功能检测(AST和ALT)及随访。
- AST/ALT升高者计算APRI评分,评分>0.5者转诊至二级和/或三级肝病专家。
- 共纳入11859名参与者进行最终分析,对照组包含349570名常规Check-up 35参与者。
主要发现
- SEAL检出488名APRI评分升高个体(4.12%)和45例进展性纤维化/肝硬化 incident 病例。
- 筛查项目中进展性纤维化/肝硬化的标准化发病率为3.83‰,对照组为3.36‰。
- SEAL与标准护理相比,纤维化/肝硬化诊断机会的比较无结论(边际OR 1.141,单侧95%CI 0.801,+Inf)。
- 事后分析排除两队列中初始诊断即为失代偿肝硬化患者后,SEAL与常规护理相比平均早期肝硬化检出机会高59%(边际OR 1.590,单侧95%CI 1.080,+Inf;SEAL 3.51‰,对照组2.21‰)。
关键数值与推荐
- APRI评分>0.5作为转诊肝病专家的阈值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Detection of patients with early cirrhosis is of importance to prevent the occurrence of complications and improve prognosis. The SEAL program aimed at evaluating the usefulness of a structured screening procedure to detect cirrhosis as early as possible. METHODS: SEAL was a prospective cohort study with a control cohort from routine care data. Individuals participating in the general German health check-up after the age of 35 ("Check-up 35") at their primary care physicians were offered a questionnaire, liver function tests (aspartate and alanine aminotransferase [AST and ALT]), and follow-up. If AST/ALT levels were elevated, the AST-to-platelet ratio index (APRI) score was calculated, and patients with a score >0.5 were referred to a liver expert in secondary and/or tertiary care. RESULTS: A total of 11,859 participants were enrolled and available for final analysis. The control group comprised 349,570 participants of the regular Check-up 35. SEAL detected 488 individuals with elevated APRI scores (4.12%) and 45 incident cases of advanced fibrosis/cirrhosis. The standardized incidence of advanced fibrosis/cirrhosis in the screening program was slightly higher than in controls (3.83‰ vs. 3.36‰). The comparison of the chance of fibrosis/cirrhosis diagnosis in SEAL vs. in standard care was inconclusive (marginal odds ratio 1.141, one-sided 95% CI 0.801, +Inf). Of note, when patients with decompensated cirrhosis at initial diagnosis were excluded from both cohorts in a post hoc analysis, SEAL was associated with a 59% higher chance of early cirrhosis detection on average than routine care (marginal odds ratio 1.590, one-sided 95% CI 1.080, +Inf; SEAL 3.51‰, controls: 2.21‰). CONCLUSIONS: The implementation of a structured screening program may increase the early detection rate of cirrhosis in the general population. In this context, the SEAL pathway represents a feasible and potentially cost-effective screening program. REGISTRATION: DRKS00013460 LAY SUMMARY: Detection of patients with early liver cirrhosis is of importance to prevent the occurrence of complications and improve prognosis. This study demonstrates that the implementation of a structured screening program using easily obtainable measures of liver function may increase the early detection rate of cirrhosis in the general population. In this context, the 'SEAL' pathway represents a feasible and potentially cost-effective screening program.
引用
- Labenz C, Arslanow A, Nguyen-Tat M, et al. Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL. J Hepatol. 2022. PMID: 35472313. doi:10.1016/j.jhep.2022.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。